HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Icecure Medical (NASDAQ:ICCM) and maintained a $3 price target for the company's stock.
November 29, 2023 | 11:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Icecure Medical's stock maintains a Buy rating and a $3 price target from HC Wainwright & Co., potentially influencing investor confidence and stock performance.
The reiteration of a Buy rating and maintenance of a $3 price target by a reputable analyst could lead to increased investor confidence and a positive short term impact on Icecure Medical's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100